Skip to content
Polygenic risk scores and breast cancer risk prediction.
Roberts E, Howell S, Evans G.
Breast. 2022 Jan 9:S0960-9776(23)00003-6. doi: 10.1016/j.breast.2023.01.003. Epub ahead of print.
Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J, Jeong K, Jun H, Kim K, Bae JM, Song MG, Yi H, Park S, Woo GU, Lee DW, Kim TY, Lee KH, Im SA.
Hum Genomics. 2023 Jan 6;17(1):2. doi: 10.1186/s40246-022-00447-3.
A polygenic two-hit hypothesis for prostate cancer.
Houlahan KE, Livingstone J, Fox NS, Kurganovs N, Zhu H, Sietsma Penington J, Jung CH, Yamaguchi TN, Heisler LE, Jovelin R, Costello AJ, Pope BJ, Kishan AU, Corcoran NM, Bristow RG, Waszak SM, Weischenfeldt J, He HH, Hung RJ, Hovens CM, Boutros PC.
J Natl Cancer Inst. 2023 Jan 5:djad001. doi: 10.1093/jnci/djad001. Epub ahead of print.
Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.
Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA, Morgan TM.
Eur Urol. 2023 Jan 4:S0302-2838(22)02870-6. doi: 10.1016/j.eururo.2022.12.021. Epub ahead of print.
Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis.
Anaclerio F, PILENZI L, Dell'elice A, Ferrante R, Gildetti S, Ferlito LM, Marinelli C, Calabrese G, Stuppia L, Antonucci I.
Front Genet. 2023 Jan 4;12:1060504. doi: 10.3389/fgene.2023.1060504.
Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants.
Subaşıoğlu A, Güç ZG, Gür EÖ, Tekindal MA, Atahan MK.
Eur J Breast Health. 2023 Jan 1;19(1):55-69. doi: 10.4274/ejbh.galenos.2022.2022-7-2.
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B.
JCO Precis Oncol. 2023 Jan;7:e2200104. doi: 10.1200/PO.22.00104.
Post navigation